Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Gardner

Showing results (31-40 of 106) with videos related to

Pageof 11
Sort By:
The AAPS Journal|February 4, 2025
Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and PregnancyIain Gardner, Aki T Heikkinen, Lloyd Wei Tat Tang, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 29, 2022
A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 SubstratesSumit Arora, Amita Pansari, Peter J Kilford, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2022
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalitiesRachel H Rose, Armin Sepp, Felix Stader, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 3, 2022
Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic FrameworkMian Zhang, Ciarán Fisher, Iain Gardner, et al.
Biopharmaceutics & Drug Disposition|March 4, 2017
Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposureWangda Zhou, Helen Humphries, Sibylle Neuhoff, et al.
Frontiers in Immunology|January 21, 2015
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn ModelManoranjenni Chetty, Linzhong Li, Rachel Rose, et al.
Clinical Pharmacology and Therapeutics|January 14, 2025
Cytokine Dynamics in Action: A Mechanistic Approach to Assess Interleukin 6 Related Therapeutic Protein-Drug-Disease InteractionsXian Pan, Katherine L Gill, Amita Pansari, et al.
The AAPS Journal|May 26, 2020
Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to AdolescentsXian Pan, Felix Stader, Khaled Abduljalil, et al.
Toxicology Research|March 12, 2016
Novel <i>in vitro</i> and mathematical models for the prediction of chemical toxicityDominic P Williams, Rebecca Shipley, Marianne J Ellis, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 28, 2022
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulatorUdoamaka Ezuruike, Mian Zhang, Amita Pansari, et al.
Pageof 11

Showing results (31-40 of 106) with videos related to

Sort By:
Pageof 11
The AAPS Journal|February 4, 2025
Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and PregnancyIain Gardner, Aki T Heikkinen, Lloyd Wei Tat Tang, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 29, 2022
A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 SubstratesSumit Arora, Amita Pansari, Peter J Kilford, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2022
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalitiesRachel H Rose, Armin Sepp, Felix Stader, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 3, 2022
Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic FrameworkMian Zhang, Ciarán Fisher, Iain Gardner, et al.
Biopharmaceutics & Drug Disposition|March 4, 2017
Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposureWangda Zhou, Helen Humphries, Sibylle Neuhoff, et al.
Frontiers in Immunology|January 21, 2015
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn ModelManoranjenni Chetty, Linzhong Li, Rachel Rose, et al.
Clinical Pharmacology and Therapeutics|January 14, 2025
Cytokine Dynamics in Action: A Mechanistic Approach to Assess Interleukin 6 Related Therapeutic Protein-Drug-Disease InteractionsXian Pan, Katherine L Gill, Amita Pansari, et al.
The AAPS Journal|May 26, 2020
Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to AdolescentsXian Pan, Felix Stader, Khaled Abduljalil, et al.
Toxicology Research|March 12, 2016
Novel <i>in vitro</i> and mathematical models for the prediction of chemical toxicityDominic P Williams, Rebecca Shipley, Marianne J Ellis, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 28, 2022
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulatorUdoamaka Ezuruike, Mian Zhang, Amita Pansari, et al.
Pageof 11